Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Bayer |
---|---|
Information provided by: | Bayer |
ClinicalTrials.gov Identifier: | NCT00044538 |
Lung cancer is among the most common cancers in the world and its incidence continues to increase. Chemotherapy for patients with Non-Small Cell Lung Cancer (NSCLC) has been under investigation for several decades and several new drugs with activity in NSCLC have been identified. These include the taxanes, which are among the most commonly used class of chemotherapy agents in clinical oncology today. The usefulness of the taxanes is limited by the development of tumor resistance to these agents. This phase II trial with BAY 59-8862 will be conducted to determine the anti-tumor efficacy of BAY 59-8862 in taxane-resistant NSCLC.
Condition | Intervention | Phase |
---|---|---|
Carcinoma, Non-Small-Cell Lung |
Drug: Bay 59-8862 |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | An Uncontrolled, Phase II Study Evaluating Anti-Tumor Efficacy and Safety of BAY 59-8862 in Patients With Taxane Resistant Non-Small Cell Lung Carcinoma (NSCLC) |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Connecticut | |
Medical Oncology/Hematology | |
Meriden, Connecticut, United States, 06450 | |
United States, Kentucky | |
Norton Healthcare Pavillion | |
Louisville, Kentucky, United States, 40202 | |
United States, Louisiana | |
Jayne Gurtler APMC | |
Metairie, Louisiana, United States, 70006 | |
United States, New York | |
Roswell Park Cancer Institute | |
Buffalo, New York, United States, 14263 | |
United States, Ohio | |
Hematology Oncology Consultants | |
Columbus, Ohio, United States, 43235 | |
United States, South Carolina | |
Spartanburg Reg. Hlth. Care Sys. | |
Spartanburg, South Carolina, United States, 29303 | |
United States, Tennessee | |
Tennessee Oncology, PC | |
Nashville, Tennessee, United States, 37203 |
Study ID Numbers: | Protocol No. 10653 |
Study First Received: | August 30, 2002 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00044538 |
Health Authority: | United States: Food and Drug Administration |
Taxane lung cancer, non-small cell NSCLC |
Thoracic Neoplasms Non-small cell lung cancer Respiratory Tract Diseases Lung Neoplasms Lung Diseases |
Taxane Carcinoma, Non-Small-Cell Lung Neoplasms, Glandular and Epithelial Carcinoma |
Respiratory Tract Neoplasms Neoplasms Neoplasms by Site Neoplasms by Histologic Type |